Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

33%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT04848909Not ApplicableActive Not Recruiting

Stereotactic Body Radiotherapy (SBRT) Post Prostatectomy

Role: collaborator

NCT04890912Not ApplicableUnknown

Stereotactic Pelvic Adjuvant Radiation Therapy in Cancers of the Uterus II

Role: collaborator

NCT01459328Phase 3Unknown

Resource-Sparing Curative Treatment for Rectal Cancer

Role: collaborator

All 3 trials loaded